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Mucosal biofilm-related fungal infections are very common, and the incidence of recurrent oral and vulvovaginal candidiasis is
significant. As resistance to azoles (the preferred treatment) is occurring, we aimed at identifying compounds that increase the
activity of miconazole against Candida albicans biofilms. We screened 1,600 compounds of a drug-repositioning library in com-
bination with a subinhibitory concentration of miconazole. Synergy between the best identified potentiators andmiconazole
was characterized by checkerboard analyses and fractional inhibitory concentration indices. Hexachlorophene, pyrvinium pa-
moate, and artesunate act synergistically with miconazole in affecting C. albicans biofilms. Synergy was most pronounced for
artesunate and structural homologues thereof. No synergistic effect could be observed between artesunate and fluconazole,
caspofungin, or amphotericin B. Our data reveal enhancement of the antibiofilm activity of miconazole by artesunate, pointing
to potential combination therapy consisting of miconazole and artesunate to treat C. albicans biofilm-related infections.
Multiple fungal species possess the capacity to form biofilmscharacterized by increased resistance against commonly
used antimycotics on both biotic and abiotic surfaces (1, 2). The
population of people susceptible to this type of infection is grow-
ing, mainly as a consequence of an extended life span, increasing
numbers of immunocompromised individuals, and use of in-
dwelling medical devices, which can serve as a substrate for bio-
film formation (3–6). Therefore, the occurrence of biofilm-asso-
ciated infections has expanded over the last several decades, and
the extent to which they impact the health of human hosts is
enormous (7, 8).
The genus Candida predominates in this type of fungal infec-
tion occurring in the oral cavity, upper and lower airways, and
gastrointestinal and urinary tracts on wounds and medical de-
vices. Such aCandidabiofilm infection can be of a rather restricted
superficial mucosal type or can evolve into hazardous invasive
candidiasis (1, 7, 9). Mucosal fungal infections are very common
and can often be treated adequately using azoles. However, the
incidence of recurrent oral and vulvovaginal candidiasis is signif-
icant, and resistance to azoles is occurring (10–13). Vaginal infec-
tions caused by Candida spp. affect 70 to 75% of women at least
once during their lives, and 40 to 50% of them experience at least
one recurrence (14). Also, immunocompromised persons, like
HIV patients, are susceptible to this type of recurrent candidiasis,
mostly involving the oral cavity (15, 16).
Mechanisms underlying the increased resistance of biofilm
cells to antimycotics are still not fully understood. However, it has
been reported that biofilm formation typically induces several
stress response pathways that impair the activity of azole drugs,
such as the induction of drug efflux pumps (17). Consequently,
cells in a biofilm are up to 1,000-fold more azole resistant than
their planktonic counterparts (1, 18), supporting the need for new
treatments.
Despite the considerable impact on human health and the
problemswith resistance related to fungal biofilms, the antimicro-
bial drug pipeline contains few novel agents that can be used
against such biofilm-related infections (19). One approach to
overcome the need for new antifungal and antibiofilm com-
pounds is to enhance the activity of existing antimycotics by com-
bining them with another compound, a strategy termed “poten-
tiation.” Such so-called potentiators can have multiple modes of
action, including the inhibition of tolerance pathways in the bio-
film or induction of increased uptake of the antimycotics.
In this study, we employed the concept of repurposing/reposi-
tioning existing market drugs. This concept has also recently
gained a lot of attention in anti-Candida research (20–25). Repur-
posing of knowndrugs is favorable from an economic perspective.
As thesemolecules have a safe toxicity profile and dosing regimens
are known, the cost of performing new clinical trials and possibly
reformulating the drug are considerably less than those for the
development of a new drug from scratch (26). For example,
toremifene citrate (a selective estrogen receptor modulator used
in the treatment of breast cancer) has been reported to be a good
potentiator of amphotericin B and caspofungin, but not of azole-
type antifungals, against Candida albicans biofilms (20). Potenti-
ation of azole antifungals by 2-adamantanamine, a derivative of
amantadine (an anti-influenza A virus drug also used to treat
some of the symptoms of Parkinson’s disease), against C. albicans
biofilms was recently demonstrated, suggesting the opportunity
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to repurpose (analogues of) other FDA-approved medications
(22).
For the above-mentioned reasons, we opted to screen a repo-
sitioning-compound library for compounds that can potentiate
the activity of the azole miconazole against C. albicans biofilms.
This concept of potentiation is often favored over the application
of single compounds, as it may lead to (i) a widened spectrum of
drug activity, (ii) a more rapid antifungal effect, (iii) synergy, (iv)
lowered dosing of toxic drugs, and (v) reduced risk of antifungal
resistance (27).
MATERIALS AND METHODS
Strains and chemicals. The C. albicans strain SC5314 (28) used in this
study was grown routinely on YPD (1% yeast extract, 2% peptone [Inter-
national Medical Products, Belgium], and 2% glucose [Sigma-Aldrich,
USA]) agar plates at 30°C. Stock solutions ofmiconazole (Sigma-Aldrich)
were prepared in dimethyl sulfoxide (DMSO) (VWR International, Bel-
gium). RPMI 1640 medium (pH 7.0) with L-glutamine and without so-
dium bicarbonate was purchased from Sigma-Aldrich and buffered with
MOPS (morpholinepropanesulfonic acid) (Sigma-Aldrich). The Phar-
makon 1600 repositioning library (MicrosourceDiscovery Systems,USA)
was supplied by the Centre of Drug Design and Discovery (Patrick Chal-
tin, Katholieke Universiteit Leuven, Belgium). Pyrvinium pamoate (salt
hydrate) and hexachlorophene were purchased from Sigma-Aldrich.
Artesunate, artemisinin, dihydroartemisinin, and artemether were pur-
chased from TCI Europe (Belgium).
Antibiofilm screening assay. A C. albicans SC5314 overnight culture,
grown in YPD, was diluted to an optical density (OD) of 0.1 (approxi-
mately 106 cells/ml) in RPMI medium, and 100 l of this suspension was
added to the wells of a round-bottom microplate (TPP Techno Plastic
Products AG, Switzerland) (30, 31). After 1 h of adhesion at 37°C, the
medium was aspirated, and the biofilms were washed with 100 l phos-
phate-buffered saline (PBS) to remove nonadherent cells, followed by
addition of 100 l RPMI 1640 medium. The biofilms were allowed to
grow for 24 h at 37°C. Then, 5Mmiconazole was added in combination
with 20 M a compound from the Pharmakon 1600 library (2 mM stock
solution inDMSO) in RPMI, resulting in a 1.1%DMSObackground. The
biofilms were incubated for an additional 24 h at 37°C. Finally, the bio-
films were washed and quantified with Cell-Titer Blue (CTB) (Promega,
USA) (32) by adding 100 l CTB diluted 1/10 in PBS to each well. After 1
h of incubation in the dark at 37°C, fluorescence was measured with a
fluorescence spectrometer (Synergy Mx multimode microplate reader;
BioTek, USA) at a ex of 535 nm and a em of 590 nm. The fluorescence
values of the samples were corrected by subtracting the average fluores-
cence value of CTB in uninoculated wells (blank). The percentage of met-
abolically active biofilm cells was calculated relative to the control treat-
ment (1.1% DMSO). Compounds were considered for retesting when
their application in the presence of 5Mmiconazole resulted in less than
60% residual metabolic activity of C. albicans biofilm cells compared to
the control and when the main reported application was not due to anti-
fungal activity.
BEC-2 determination assay. To determine the biofilm eradication
concentration 2 (BEC-2) values (the minimal concentration of the com-
pound that causes a 2-fold decrease in biofilm metabolic activity) for the
respective compounds, C. albicans SC5314 biofilms were grown in a
round-bottom microplate as described above. Then, the biofilms were
washed with 100 l PBS, and 100 l of a concentration series of the
compounds in RPMI was added to the biofilms, resulting in a 0.5%
DMSO background. The biofilms were incubated for 24 h at 37°C, after
which they were washed and quantified with CTB as described above.
Biofilm checkerboard assay. In order to determine possible synergis-
tic interactions between antifungal agents on one hand and identified
potentiators on the other hand against C. albicans SC5314, checkerboard
analysis was used. C. albicans biofilms were grown as described above. A
combination of antifungal compound and potentiator, 2-fold diluted
across rows and columns of amicroplate, respectively, was added (DMSO
background, 0.6%). After 24 h of incubation at 37°C, the biofilms were
quantified by the CTB method. Synergism was determined by fractional
inhibitory concentration index (FICI) calculations (20, 33). The FICI was
calculated by the following formula: FICI  [C(BEC-2A)/BEC-2A] 
[C(BEC-2B)/BEC-2B], in which C(BEC-2A) and C(BEC-2B) are the
BEC-2 values of the antifungal drugs in combination and BEC-2A and
BEC-2B are the BEC-2 values of antifungal drugs A and B alone. The
interaction was defined as synergistic for a FICI value of0.5, indifferent
for 0.5 FICI 4, and antagonistic for a FICI value of4.0 (33).
Planktonic checkerboard assay. Synergistic action on the growth of
planktonic cells was determined by FICI calculations as described above.
MIC-2 values (the minimal concentration of the compound that causes a
2-fold reduction of planktonic cell growth) were used instead of BEC-2
values. To determine the MIC-2 values for the respective compounds, we
utilized conditions similar to those used by Kaneko et al. (24). Briefly, an
overnight culture of C. albicans SC5314 was diluted to an optical density
of 0.1 in synthetic complete (SC) medium (1% complete amino acid sup-
plement mixture [CSM] [MP Biomedicals, USA], 1% yeast nitrogen base
[YNB], 2% glucose [Sigma-Aldrich]) in combination with a concentra-
tion series of the compounds 2-fold diluted across the rows of the micro-
plate. After 24 h of growth in the presence of the compounds at 37°C,
growth was quantified by measuring the OD at 490 nm. The percent
growth reduction was calculated relative to the control treatment (0.5%
DMSO). In the checkerboard assay, a combination of antifungal com-
pound and potentiator, 2-fold diluted across rows and columns of a mi-
croplate, respectively, was added (DMSO background, 0.6%) to the di-
luted overnight culture. After 24 h of incubation at 37°C, the OD was
measured at 490 nm.
Reactive oxygen species (ROS) detection assay. C. albicans biofilms,
grown as described above, were incubated for 2 to 24 h with artesunate,
miconazole, or a combination of both compounds in RPMI at 37°C. After
washing the biofilm cells with PBS, the biofilms were incubated in
the presence of 10 M 2=,7=-dichlorodihydrofluorescein diacetate
(H2DCFDA) (Invitrogen, USA) in PBS for 1 h at 37°C. Fluorescence was
measured at a ex of 470 nm and a em of 525 nm.
Statistical analysis. The results were analyzed for statistical signifi-
cance by an unpaired two-tailed Student t test. Values were considered to
be statistically significant when the P value was0.05.
RESULTS AND DISCUSSION
Screening for potentiators of the antibiofilmactivity ofmicona-
zole against C. albicans biofilms. We screened 1,600 off-patent
drugs and other bioactive agents (the Pharmakon 1600 reposi-
tioning library) to identify compounds that can enhance the anti-
biofilm activity of miconazole against mature biofilms. First, we
determined the effects of a concentration series of miconazole
alone on mature C. albicans biofilms and found that the BEC-2 of
miconazole is 92.3 13.0 M (Fig. 1). We opted to add a combi-
nation of the library compound (20 M) and a subantibiofilm
concentration of miconazole (5 M, resulting in 90 to 100% re-
maining biofilm activity). We identified 8 compounds that re-
sulted in less than 60% residual metabolic activity of the C. albi-
cans biofilm cells when applied in the presence of 5 M
miconazole and with a main reported application other than an-
tifungal activity. They are listed in Table 1, alongwith their known
medical applications.
This initial screening strategy did not discriminate between
compounds that affect the biofilm on their own and compounds
that enhance the antibiofilm activity of miconazole. To discrimi-
nate between these two possibilities, we examined the antibiofilm
activities of 20 M these 8 compounds in the presence and ab-
sence of 5 M miconazole. In Table 1 the compounds are sorted
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based on the ratio between the residual metabolic activity of the
biofilm cells after treatment with the compound in combination
with miconazole and that after treatment with the compound
alone. For compounds with a ratio of 1, there seems to be an
increased antibiofilm effect of the combination with miconazole
compared to that of the compound alone. However, many of the
top compounds in the list are also very active on their own against
C. albicans biofilms, as illustrated by their BEC-2 values.
Hexachlorophene, pyrvinium pamoate, and artesunate act
synergistically with miconazole to diminish C. albicans biofilm
activity. The top 3 compounds, based on the ratio between their
effects in combination with miconazole and alone (hexachloro-
phene, pyrvinium pamoate, and artesunate), were selected to de-
termine whether they act synergistically with miconazole against
C. albicans biofilms. Hexachlorophene is a topical anti-infective
drug often used in soaps, liquid detergents, and cosmetics during
the 1960s, but its use has been questioned because of its toxicity
(34). Pyrvinium pamoate is an antihelmintic drug that, when
taken orally, is safe even at high doses, but systemic absorption
from the gut is minimal (35). Artesunate, a semisynthetic deriva-
tive of artemisinin extracted from Artemisia annua (sweet worm-
wood), is one of the most widely applied antimalarial drugs and is
recommended by the World Health Organization (36). We per-
formed checkerboard analysis and calculated the corresponding
FICI to determine the synergy (FICI  0.5) for each of the com-
pounds in combinationwithmiconazole (Table 2). Note that only
one strain was used in this study, and clinical strains may behave
differently.
Although all three compounds establish a synergistic interac-
tion with miconazole, artesunate is the only potentiator that has
almost no antibiofilm activity against C. albicanswhen used alone
(according to the BEC-2 value [Table 1]), resulting in the lowest
FICI values (Table 2). Additionally, combinations with the com-
pound resulted in the highest reduction of the BEC-2 value of
miconazole, as illustrated in Fig. 1 and quantified in Table 2 (fold
change). Therefore, the compound was selected for further exten-
sive characterization.
The mechanism of action of artesunate (and structural homo-
logues thereof, collectively called artemisinins) in the treatment of
malaria is complex and is only partially understood (37). Much
effort is still expended in the elucidation of the modes of action in
both Plasmodium falciparum (38–40) and yeast (41–43). A yeast
model uncovered a role of mitochondria during the action of
artemisininswith an important function for the electron transport
chain and subsequent damage by locally generated ROS (41). We
observed only slightly increased ROS accumulation in C. albicans
biofilm cells treated with artesunate concentrations starting from
20 M and a more pronounced ROS accumulation upon incuba-
FIG 1 Metabolic activity ofC. albicans biofilms treated with a combination of artesunate andmiconazole (checkerboard assay). The control curve ofmiconazole
alone without artesunate (diamonds) and the curves of combinations of miconazole with 0.625 (circles), 1.25 (crosses), 2.5 (squares), or 5 (triangles) M
artesunate are shown. The values are the means standard errors of the mean (SEM) of at least 3 independent biological replicates.
TABLE 1 Hits from the miconazole potentiator screen as well as the
BEC-2 value of each compound alone is indicated
Compound Applicationa
Ratio of effects
(combination/
alone)b
BEC-2c
(M)
Hexachlorophene Anti-infective (topical) 2.29 9.3 0.65
Pyrvinium pamoate Antihelmintic 2.10 3.9 0.13
Artesunate Antimalarial 1.69 200
Broxyquinoline Antiinfectant, disinfectant 1.42 1.2 0.31
Dihydroartemisinin Antimalarial 1.31 200
Gentian violet Antibacterial,
antihelmintic
1.18 1.5 0.08
Bithionate
disodium
Anthelmintic, antiseptic 1.09 6.0 1.56
Nitroxoline Antibacterial 0.94 3.1 1.67
a As stated in the Pharmakon 1600 information sheet.
b The ratio of the antibiofilm effect of 20 M the repurposed compounds in
combination with 5 M miconazole and alone.
c Means standard errors of the mean (SEM) of at least 3 independent biological
replicates.
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tion with miconazole alone (as reported previously [44, 45]), but
no increased ROS accumulation due to the combination of both
compounds could be observed (data not shown).
Artesunate does not increase the activities of fluconazole,
amphotericin B, and caspofungin against C. albicans biofilms.
We assessed whether artesunate could also increase the activities
of other types of azoles, like fluconazole, against C. albicans bio-
films. Fluconazole showedno significant antibiofilm activity on its
own (BEC-2  500 M) or in combination with 20 M artesu-
nate (BEC-2 500 M).
Kaneko et al. recently showed that artesunate could enhance
the activity of the azole fluconazole against planktonic C. albicans
SC5314 cultures (24). Therefore, we checked whether artesunate
could increase the antifungal activity ofmiconazole or fluconazole
on planktonic cells by checkerboard analyses (data not shown). A
concentration of 5 M artesunate reduced the MIC-2 values of
miconazole and fluconazole (0.11  0.01 M and 3.25  0.43
M, respectively) by 2-fold and 1.6-fold, respectively, in line with
the previously reported data (24). However, artesunate did not act
synergistically with miconazole or fluconazole on planktonic C.
albicans cells, as the resulting FICI was higher than 0.5.
Next, we determined whether artesunate could increase the
activities of other types of antimycotics, like amphotericin B and
caspofungin, against C. albicans biofilms (see Fig. S1 and S2 in the
supplemental material). However, the BEC-2 values of amphoter-
icin B (1.8 0.4M) and caspofungin (0.4 0.06M) remained
almost unaffected by the presence of all tested concentrations of
artesunate, resulting in FICI values between 0.5 and 2. Conse-
quently, the interaction of artesunate with amphotericin B and
caspofungin is defined as indifferent.
Structural homologues of artesunate act synergistically with
miconazole against C. albicans biofilms. Table 1 suggests that a
structural homologue of artesunate, namely, dihydroartemisinin,
is also capable of increasing the activity of miconazole against C.
albicans biofilms. Interestingly, one of the compounds that is on
the border of the cutoff for the top 8 was another homologue of
these compounds, namely, artemisinin (resulting in 61% biofilm
metabolic activity in the combination screen [data not shown]).
One other structural homologue was available to us during this
study, namely, artemether. Via checkerboard analyses, we could
TABLE 2 Synergistic activities of the potentiators hexachlorophene,
pyrvinium pamoate, and artesunate with miconazole against C. albicans
biofilms
Drug or
combination
Potentiator
concn
(M)
Miconazole
BEC-2
(M)a P value
Fold
changeb FICI
Miconazole alone 92.3 13.0 NAc NA NA
Miconazole
hexachlorophene
2.5 9.3 3.4 0.0158 9.9 0.370
1.25 15.7 6.1 0.0228 5.9 0.305
0.625 18.5 4.8 0.0265 5.0 0.268
0.3125 26.0 8.0 0.0397 3.6 0.315
Miconazole
pyrvinium
pamoate
1.25 9.3 4.1 0.0164 10.0 0.421
0.625 18.9 7.7 0.0284 4.9 0.365
0.3125 28.7 11.6 0.0482 3.2 0.391
Miconazole
artesunate
5 4.0 0.9 0.0050 22.9 0.069
2.5 5.2 0.7 0.0055 17.7 0.069
1.25 12.2 4.3 0.0194 7.5 0.139
0.625 15.2 3.6 0.0234 5.9 0.171
a The BEC-2 values of hexachlorophene, pyrvinium pamoate, and artesunate are 9.3,
3.9, and200 M, respectively. The BEC-2 values are the means SEM of at least 3
independent biological replicates and were analyzed for statistical significance by an
unpaired two-tailed Student t test (against the control treatment of miconazole alone).
b Fold change, fold increase of biofilm activity of miconazole due to the combination,
calculated as follows: (BEC-2 of miconazole alone)/(BEC-2 of miconazole in
combination).
c NA, not applicable.
FIG 2 Metabolic activity of C. albicans biofilms treated with combinations of miconazole and artesunate, artemisinin, dihydroartemisinin, or artemether. The
control curve of miconazole alone (diamonds) and the curves of miconazole with 5 M artesunate (triangles), artemisinin (circles), dihydroartemisinin
(crosses), or artemether (squares) are shown. The values are the means SEM of at least 3 independent biological replicates.
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show that the observed synergy between artesunate and micona-
zole against C. albicans biofilms is not specific only to artesunate,
but also applies to artemisinin, dihydroartemisinin, and arte-
mether (collectively called artemisinin derivatives or artemis-
inins) (the BEC-2 values for all single compoundswere200M)
(Fig. 2). A concentration of 5 M of these compounds with mi-
conazole resulted in 6.2-fold, 8.3-fold, and 11.4-fold reductions in
the BEC-2 value of miconazole (resulting in maximal FICI values
of 0.186, 0.145, and 0.112) for artemisinin, dihydroartemisinin,
and artemether, respectively. These data suggest that synergistic
action with miconazole is a characteristic of all artemisinins, im-
plying that the activity is probably attributable to the core chem-
ical structure (a sesquiterpene scaffold with an endoperoxide
bridge) of this family.
We conclude that combinations ofmiconazole with artesunate
or other artemisinins could be a novel therapeutic strategy to treat
C. albicans biofilm-related infections.
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